Navigation Links
ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions

Testing Will Help Advance Technology to Find a Faster, More Accurate and Repeatable Method for Drug-Particle Sizing

PITTSBURGH, April 1 /PRNewswire/ -- ChemImage, ( today announces a strategic research partnership with Next Breath, LLC (, a leading Contract Research Organization (CRO) to further validate ChemImage's Raman Chemical Imaging for bioequivalence applications for nasal spray suspensions.

Baltimore, MD-based Next Breath focuses on conducting in vitro bioequivalence testing for nasal sprays and chemistry, manufacturing and controls (CMC) testing for inhalation and nasal spray products, and is particularly interested in advancing the technology to find a faster and reproducible method for drug-particle sizing relative to bioequivalence studies for nasal spray suspensions.

"We are proud to partner with Next Breath because our goal at ChemImage is to validate our bioequivalence testing methodology," said Ryan Priore, Senior Scientist, ChemImage. "Pharmaceutical companies, particularly generic drug manufacturers focused on nasal spray suspensions, are looking to improve their time-to-market through the use of better imaging technology. The potential payoff is a faster, more accurate and safe way to bring the drug to market."

ChemImage, one of the world's leading chemical and biological imaging technology solutions companies, will be partnering with Next Breath to compare optical microscopy to Raman Chemical Imaging, specifically ChemImage's FALCON II(TM) Wide-Field Raman Chemical Imaging System.

The FALCON II enables drug manufacturers to perform chemical imaging of particles in droplets to distinguish the identity, particle size distribution of drug and other substances, aggregation, and the correlation about the location of the material in the formulation -- something drug makers have been unable to achieve in the past with standard optical microscopy as part of bioequivalence testing.

"Clearly, ChemImage has the potential to advance the ability of drug manufacturers to more accurately assess their risk when going into clinical trials by providing them with a more objective active ingredient particle size analysis between the Test and Reference Drug Product. Our work with ChemImage will help validate their Raman Chemical Imaging technology and services to perform in vitro drug particle size distribution measurements," said Julie Suman, President, Next Breath, LLC.

ChemImage's FALCON II is currently available for sale across international markets. ChemImage also offers imaging lab services for companies interested in expediting bioequivalence testing. The company expects the additional validation testing to be conducted in 2009 and 2010.

ChemImage and Next Breath will be attending the Nasal Drug Delivery Conference on April 1st - 2nd, 2009 in London.

About Next Breath

Next Breath is a contract services provider for pharmaceutical, biotech and medical device companies that bring new inhalation and nasal products to market. The company provides an array of in-vitro services, from pre-clinical formulation development to analytical testing in support of submissions to regulatory agencies. Its mission is to serve as an effective liaison between innovators of promising drug molecules and inventors of pulmonary and nasal drug delivery devices.

About ChemImage

ChemImage Corporation, headquartered in Pittsburgh, is a world leader in Chemical Imaging technologies; provides instrumentation, software, lab services and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Its state-of-the-art Chemical Imaging technology can help to reveal critical chemical and biological information about processes, products and services.

SOURCE ChemImage
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Two nanostructures are better than one
3. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
4. NIST team develops novel method for nanostructured polymer thin films
5. Smart insulin nanostructures pass feasibility test, UT study reports
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. Researchers outline structure of largest nonvirus particle ever crystallized
8. CME LLC Restructures, Announces Its New Executive Management Team
9. Ames Laboratory researchers solve fuel-cell membrane structure conundrum
10. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
11. DRI Capital Launches Structured Finance Fund
Post Your Comments:
(Date:11/26/2015)... England , November 26, 2015 ... innovative medical device company specializing in imaging technologies, announced today ... European Commission as part of the Horizon 2020 European Union ... carry out a large-scale clinical trial in breast cancer. ... (Logo: , --> --> ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
Breaking Biology Technology:
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
(Date:10/27/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... has adopted the Synaptics ® ClearPad ® ... its newest flagship smartphones, the Nexus 5X by LG ... --> --> Synaptics works closely ... collaboration in the joint development of next generation technologies. ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 ... in modern authentication and a founding member of the ... its latest version of the Nok Nok™ S3 Authentication ... standards-based authentication that supports existing and emerging methods of ... ideal for organizations deploying customer-facing applications that require Internet ...
Breaking Biology News(10 mins):